tetano
Editor, Senior Moderator
Intern Med
. 2023 Feb 1.
doi: 10.2169/internalmedicine.1027-22. Online ahead of print.
Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination
Seiji Kobayashi[SUP] 1 [/SUP], Kazunori Fugo[SUP] 2 [/SUP], Ryo Hatano[SUP] 3 [/SUP], Kazuto Yamazaki[SUP] 2 [/SUP], Chikao Morimoto[SUP] 3 [/SUP], Hiroyuki Terawaki[SUP] 1 [/SUP]
Affiliations
Abstract
As coronavirus disease 2019 (COVID-19) vaccine booster campaigns progress worldwide, new reports of complications following COVID-19 vaccination have emerged. We herein report a case of new-onset anti-glomerular basement membrane (GBM) disease concomitant with myeloperoxidase-antineutrophil cytoplasmic antibody positivity concurrent with high levels of interleukin (IL)-26 following the second dose of the Pfizer-BioNTech COVID-19 vaccine. The temporal association with vaccination in this case suggests that an enhanced neutrophilic immune response through IL-26 may have triggered necrotizing glomerulonephritis and a T-cell-mediated immune response to GBMs, leading to the development of anti-GBM antibodies, with an enhanced B-cell response after the vaccination triggering anti-GBM IgG and the onset of anti-GBM disease.
Keywords: ANCA-associated glomerulonephritis; Anti-GBM disease; IL-26; mRNA-based COVID-19 vaccine; pharmacovigilance.
. 2023 Feb 1.
doi: 10.2169/internalmedicine.1027-22. Online ahead of print.
Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination
Seiji Kobayashi[SUP] 1 [/SUP], Kazunori Fugo[SUP] 2 [/SUP], Ryo Hatano[SUP] 3 [/SUP], Kazuto Yamazaki[SUP] 2 [/SUP], Chikao Morimoto[SUP] 3 [/SUP], Hiroyuki Terawaki[SUP] 1 [/SUP]
Affiliations
- PMID: 36725042
- DOI: 10.2169/internalmedicine.1027-22
Abstract
As coronavirus disease 2019 (COVID-19) vaccine booster campaigns progress worldwide, new reports of complications following COVID-19 vaccination have emerged. We herein report a case of new-onset anti-glomerular basement membrane (GBM) disease concomitant with myeloperoxidase-antineutrophil cytoplasmic antibody positivity concurrent with high levels of interleukin (IL)-26 following the second dose of the Pfizer-BioNTech COVID-19 vaccine. The temporal association with vaccination in this case suggests that an enhanced neutrophilic immune response through IL-26 may have triggered necrotizing glomerulonephritis and a T-cell-mediated immune response to GBMs, leading to the development of anti-GBM antibodies, with an enhanced B-cell response after the vaccination triggering anti-GBM IgG and the onset of anti-GBM disease.
Keywords: ANCA-associated glomerulonephritis; Anti-GBM disease; IL-26; mRNA-based COVID-19 vaccine; pharmacovigilance.